CLINICAL TRIAL

EBT-101 for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

EnrollingByInvitation · 18+ · All Sexes · Saint Louis, MO

Long-Term Follow-Up Study of HIV-1 Infected Adults Who Received EBT-101

See full description

About the trial for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Treatment Groups

This trial involves 2 different treatments. EBT-101 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
EBT-101
BIOLOGICAL
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Signed Informed Consent
Participants who received the investigational study intervention EBT-101 in a previous intervention study
View All
Odds of Eligibility
High>50%
You meet most of the criteria! It's probably a good idea to apply to 1 other trial just in case this doesn't work out.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 15 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 15 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 15 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether EBT-101 will improve 1 primary outcome in patients with Human Immunodeficiency Virus Type 1 (HIV-1) Infection. Measurement will happen over the course of 15 years.

Long-term safety of EBT-101
15 YEARS
Long-term safety of EBT-101 will be assessed based on incidence and severity of clinically significant adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 15 years
15 YEARS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many people get human immunodeficiency virus type 1 (hiv-1) infection a year in the United States?

Among all people living in a given population, 1 in 35 might be HIV-infected at time of survey. HIV-infected persons represent a risk group that will be included in the growing epidemic. In addition, as with any age-adjusted survey, HIV-infected persons are at higher risk than the general population of developing a HIV-related illness.

Anonymous Patient Answer

What causes human immunodeficiency virus type 1 (hiv-1) infection?

HIV-1 infection causes disease principally as a result of disruption of the host's immune system rather than as a result of direct infection of immune cells.

Anonymous Patient Answer

Can human immunodeficiency virus type 1 (hiv-1) infection be cured?

AIDS has a good prognosis if diagnosis is made soon after exposure to HIV or acquisition of HIV infection during pregnancy. The risk of transmission from an HIV-positive mother to her child, if the child becomes infected during childbirth and/or if the child is infected postnatally are low, the child is generally safer from HIV than the rest of the population. Even people who have passed through multiple STIs or who have tested HIV-infected should assume that their risk for developing AIDS is greater than the rest of the population. Children infected in utero or at birth with HIV-1 disease that is not immediately life-threatening should receive lifelong antiviral treatment to prevent disease progression within the first year of life if they live in industrialized countries.

Anonymous Patient Answer

What are common treatments for human immunodeficiency virus type 1 (hiv-1) infection?

Despite increased use of antiretroviral therapy (ART), there are common ART regimens (tenofovir/emtricitabine/tenafovir; tenofovir/emtricitabine/efavirenz; nevirapine/emtricitabine/tenofovir; efavirenz/emtricitabine/tenofovir; abacavir/lamivudine/zidovudine/tenofovir; lopinavir/ritonavir/emtricitabine/tenofovir), and patients often cite their medications as the things that work better for them.

Anonymous Patient Answer

What are the signs of human immunodeficiency virus type 1 (hiv-1) infection?

To help to develop an effective clinical diagnostic tool for identifying those with HIV/AIDS who are at high risk for transmitting the virus, further research with a larger samples is necessary. In addition, future investigations need to examine viral and immune parameters at different levels, to investigate the possibility of developing new preventive strategies to reduce the further spread of HIV-1.

Anonymous Patient Answer

What is human immunodeficiency virus type 1 (hiv-1) infection?

HIV-1 is a retrovirus that causes AIDS by destroying the body's T-lymphocytes. It can be transmitted in the blood through the semen, vaginal fluids, or breast milk of a person who has AIDS and causes AIDS by destroying the body's T-lymphocytes. HIV-1 has no cure. An alternative mode of transmission of HIV-1 by sexual intercourse with an HIV-1 positive person is still unknown, but recent research suggests that HIV-1 may be a sexual transmitted infection.

Anonymous Patient Answer

How does ebt-101 work?

In a recent study, findings suggest a unique mechanism that ebt-101 induces weight loss with low toxicity and without compromising the ability of hDDC to be produced. While this may be a valuable strategy for treating obesity in other diseases, the use of ebt-101 in hDDC-deficient persons with HIV-1 infection is promising; studies are underway to examine the most efficacious and safest administration route and dosage for those with impaired hDDC production.

Anonymous Patient Answer

Does ebt-101 improve quality of life for those with human immunodeficiency virus type 1 (hiv-1) infection?

Recent findings demonstrate the benefits of oral ebt-101 for HIV patients as it decreased viral load with greater CD4 and CD8 counts, improved QOL, and was well tolerated by the participants. Recent findings also support our work in a Phase I, open-label, open-cycle, phase II, dose-escalating randomized-controlled trial.

Anonymous Patient Answer

What are the latest developments in ebt-101 for therapeutic use?

This drug for therapeutic use is an oral administration form of an active ingredient with an improved bioavailability as compared to the parent drug. This new oral formulation can result in a further reduction in the oral bioavailability of the parent agent.

Anonymous Patient Answer

How serious can human immunodeficiency virus type 1 (hiv-1) infection be?

AIDS has been described as a deadly disease, but this should not be extrapolated from the HIV infections prevalent in an U.S. prison. Although the life expectancy after diagnosis of AIDS is now about 2 years at the current U.S. AIDS case fatality rate of 18%, patients with HIV-1 infection can live for nearly 4 years with full access to medical care and supportive treatment.

Anonymous Patient Answer

What is the latest research for human immunodeficiency virus type 1 (hiv-1) infection?

Although the new therapeutic drugs and strategies for HIV-1 infection are being developed, the latest research is still focused on the biological mechanisms of the pathogenesis of the HIV-1 infection. So there is much to be discovered in the future.

Anonymous Patient Answer

What is the primary cause of human immunodeficiency virus type 1 (hiv-1) infection?

In a recent study, findings are in favor of the hypothesis that HIV-1 infection is the main risk factor for acquiring the virus and the only identifiable etiological factor for chronic infection.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Human Immunodeficiency Virus Type 1 (HIV-1) Infection by sharing your contact details with the study coordinator.